The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 70.00
Bid: 55.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 30.00 (54.545%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 75.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

30 Jul 2020 07:00

RNS Number : 5306U
Biome Technologies PLC
30 July 2020
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR")

 

30 July 2020

 

 

Biome Technologies plc

 

("Biome", "the Company" or "the Group")

 

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the six months ended 30 June 2020. The Company's unaudited interim results are expected to be announced on 24 September 2020.

 

Total Group revenues for the first half of the year, including government grant income, were £2.6m (H1 2019: £3.6m), in line with the Board's expectations.

 

As anticipated, the Bioplastics division performed well despite the upheaval caused by Covid-19 with a 53% increase in revenues over the same period in the prior year. The revenues of the Stanelco RF division, however, were compromised by both over-capacity in the fibre optic market and the slow-down in industrial activity caused by Covid-19, which remains ongoing.

 

The Group's cash position as at 30 June 2020 was £1.1m (31 March 2020: £1.8m), reflecting Group trading performance and an expected increase in the working capital requirement of the Bioplastics division to support the ongoing growth in that business. The Group has no debt.

 

The Group continues its manufacturing and development operations whilst ensuring the safety of staff and in conformance with Government advice. The Group has continued to make use of the UK Government "furlough scheme" and has curtailed discretionary operational and capital expenditure.

 

Bioplastics Division

 

Revenues in the Bioplastics division continued to grow during H1 2020, reaching £2.2m for the period including government grant income of £0.1m (H1 2019: £1.4m including government grant income of £0.2m). Revenue in the second quarter was £1.2m, slightly above the first quarter and representing a new record for the division, despite the disruption caused by the pandemic.

 

The strong performance in the period was underpinned by increased sales of outer packaging for the USA coffee market and by growing revenues for rigid ring materials for the coffee-pod market. Despite the lockdown and supply chain constraints in both Europe and the USA, the Bioplastics division's work flows proved resilient and production output met customer requirements throughout the first half.

 

We are working with an expanding list of potential new customers in the USA and developmental work in that context continues with some vigour. The business is well positioned to exploit further opportunities in this growing market.

 

The division's medium-term research activities in Industrial Biotechnology continue, which include the development of a new range of performance polymers with properties which are expected to improve the existing generation of products. This work, taking place at the universities of Nottingham and York, is supported by government grants. Whilst university closures have slowed this work, post period end, the division has received an Innovate UK Continuity Grant of £63,000 to support the recovery of time lost on this work.

 

Stanelco RF Technologies Division

 

Revenues for the first half of 2020 in the Stanelco RF division were £0.4m (H1 2019: £2.2m).

 

A substantial proportion of the Stanelco RF division's revenues are normally derived from the production and maintenance of furnaces for the manufacture of fibre optic cable. Overcapacity in the fibre optic cable market, apparent from late 2018, has been exacerbated by the pandemic as telecommunication companies have suffered restrictions on cable deployment activity and international trade disputes have slowed the deployment of 5G. These factors have led to temporary shut-downs of a number of manufacturing facilities at Stanelco RF's customers, with a consequential reduction in the requirement for Stanelco RF to provide equipment, spares and service support. The expectation is that in the long term, the fibre optic market will benefit from the pandemic through the enhanced pace of global digitisation required to meet the demands of, for example, increased home working and the 5G roll-out. However, in the short term, demand is likely to remain weak.

 

The division also provides induction heating and welding equipment to various end markets in the UK and continental Europe. Activity in these markets in the second quarter was very weak, with many facilities closed and customers deferring the purchase of capital goods. The Company is pleased that in the last few weeks, the enquiry level has increased and there have been some small contract wins albeit overall demand levels remains subdued.

Outlook

 

The Board has sought to provide investors with as clear a view as possible on its expectations for the Company during this exceptional year. During the first half of 2020, the Group's two divisions performed in line with the expectations communicated and considered appropriate by the Board in April 2020, during the early stages of the Covid-19 pandemic.

 

The Bioplastics division now has a range of products with a more predictable and improving growth profile and is selling in the USA predominantly, into a buoyant home-delivered coffee sector. Its orderbook now extends further forward than the division has ever experienced before, and the Board is therefore confident on the outlook for the Bioplastics division for the remainder of the current financial year.

 

Covid-19 has had a much greater impact on the Stanelco RF division. The fibre optic cable market remains oversupplied and the current pace of recovery in demand in the industrial goods sector now appears slower and more uncertain than was anticipated in April 2020. Whilst refilling of the division's orderbook has begun in a modest manner, significant further momentum would be required in the second half of the year to meet the expectations previously set by the Board. As a result, the Board has concluded that it is necessary to revise downwards the revenue expectations for the Stanelco RF division for the second half of the year.

 

 

 

- Ends -

 

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

David Hughes, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

 

 

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKCBKOBKDQOB
Date   Source Headline
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.